| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000165 | Mapk cascade | Increases phenotype | PMID:21424555 |
| GO:0001662 | Behavioral fear response | Affects phenotype | PMID:24358339 |
| GO:0002027 | Regulation of heart rate | Increases phenotype | PMID:10672977; PMID:10672977; PMID:11981223; PMID:1745709; PMID:7796714; PMID:10780258; PMID:10780258; PMID:12755456; PMID:1607544; PMID:16160708; PMID:19303723; PMID:2162543; PMID:2829241; PMID:3122247; PMID:3244716; PMID:7587975; PMID:7870911; PMID:7884020; PMID:8229755; PMID:10854839; PMID:10854839; PMID:2314194; PMID:11442576; PMID:4028628; PMID:19349312; PMID:23024753; PMID:2314194; PMID:2392777; PMID:2829241; PMID:7796714; PMID:8229755; PMID:9831120 |
| GO:0004069 | L-aspartate:2-oxoglutarate aminotransferase activity | Increases phenotype | PMID:30393195 |
| GO:0004784 | Superoxide dismutase activity | Increases phenotype | PMID:29475069 |
| GO:0006306 | Dna methylation | Affects phenotype | PMID:18382688 |
| GO:0006309 | Apoptotic dna fragmentation | Increases phenotype | PMID:10379789; PMID:10604926; PMID:10774788; PMID:11392460; PMID:15685203; PMID:19183502; PMID:9166738 |
| GO:0006606 | Protein import into nucleus | Increases phenotype | PMID:31059705 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:30393195 |
| GO:0006914 | Autophagy | Increases phenotype | PMID:31494168 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:10065903; PMID:10379789; PMID:10604926; PMID:10774788; PMID:11368239; PMID:11392460; PMID:11392460; PMID:15685203; PMID:12639677; PMID:15365088; PMID:15371167; PMID:15677681; PMID:17084983; PMID:17635674; PMID:18974856; PMID:19183502; PMID:21424555; PMID:29475069; PMID:9166738 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:29475069 |
| GO:0006979 | Response to oxidative stress | Increases phenotype | PMID:15857623; PMID:16012352; PMID:16956698; PMID:18593214; PMID:18952886; PMID:19822180; PMID:20566328; PMID:21424555; PMID:8059426 |
| GO:0007049 | Cell cycle | Decreases phenotype | PMID:18593214 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:10379789 |
| GO:0007601 | Visual perception | Decreases phenotype | PMID:31730894 |
| GO:0007611 | Learning or memory | Decreases phenotype | PMID:31730894 |
| GO:0007626 | Locomotory behavior | Increases phenotype | PMID:17555897; PMID:19879923 |
| GO:0008217 | Regulation of blood pressure | Increases phenotype | PMID:10433872; PMID:10433872; PMID:2314194; PMID:8287915; PMID:9657630; PMID:10672977; PMID:10672977; PMID:10780258; PMID:12755456; PMID:12957222; PMID:1607544; PMID:16160708; PMID:2038082; PMID:2829241; PMID:3122247; PMID:3244716; PMID:7587975; PMID:7796714; PMID:7884020; PMID:8229755; PMID:10780258; PMID:1171051; PMID:11981223; PMID:1646895; PMID:1745709; PMID:12957222; PMID:1646895; PMID:1646895; PMID:8125204; PMID:19303723; PMID:7870911; PMID:7796714; PMID:7840303; PMID:8125204; PMID:8229755; PMID:8287915 |
| GO:0008219 | Cell death | Increases phenotype | PMID:16956698; PMID:18952886; PMID:25933444 |
| GO:0008283 | Cell population proliferation | Increases phenotype | PMID:1452400; PMID:16903860; PMID:18593214; PMID:20104651; PMID:7782154 |
| GO:0008344 | Adult locomotory behavior | Increases phenotype | PMID:25724654; PMID:25724654; PMID:27053203; PMID:27053203 |
| GO:0008361 | Regulation of cell size | Increases phenotype | PMID:15685203 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:29475069; PMID:30393195; PMID:31059705 |
| GO:0016049 | Cell growth | Decreases phenotype | PMID:29475069 |
| GO:0018158 | Protein oxidation | Increases phenotype | PMID:30393195 |
| GO:0022900 | Electron transport chain | Affects phenotype | PMID:16638611 |
| GO:0023041 | Neuronal signal transduction | Increases phenotype | PMID:32209479 |
| GO:0030534 | Adult behavior | Affects phenotype | PMID:27126842 |
| GO:0031987 | Locomotion involved in locomotory behavior | Increases phenotype | PMID:27506785; PMID:28194001; PMID:28194001; PMID:35597300; PMID:35597300 |
| GO:0032125 | Micronucleus organization | Increases phenotype | PMID:37271276 |
| GO:0032225 | Regulation of synaptic transmission, dopaminergic | Affects phenotype | PMID:23499958 |
| GO:0033686 | Positive regulation of luteinizing hormone secretion | Increases phenotype | PMID:12893845 |
| GO:0034970 | Histone h3-r2 methylation | Affects phenotype | PMID:27506785 |
| GO:0035176 | Social behavior | Decreases phenotype | PMID:23800218 |
| GO:0042116 | Macrophage activation | Decreases phenotype | PMID:1452400 |
| GO:0042310 | Vasoconstriction | Increases phenotype | PMID:10433872; PMID:10433872; PMID:9657630; PMID:10815846; PMID:9459471; PMID:12730277; PMID:15313520; PMID:1543310; PMID:1607544; PMID:1906905; PMID:2358608; PMID:7763124; PMID:1906905; PMID:2392777; PMID:2735952; PMID:7631697; PMID:8944401 |
| GO:0042311 | Vasodilation | Increases phenotype | PMID:12044126; PMID:12730277; PMID:7763124; PMID:8059426 |
| GO:0042416 | Dopamine biosynthetic process | Increases phenotype | PMID:27129946 |
| GO:0044026 | Dna hypermethylation | Affects phenotype | PMID:23543013 |
| GO:0044028 | Dna hypomethylation | Affects phenotype | PMID:23543013 |
| GO:0044030 | Regulation of dna methylation | Affects phenotype | PMID:29412867 |
| GO:0046466 | Membrane lipid catabolic process | Increases phenotype | PMID:16012352; PMID:19822180; PMID:2886651; PMID:8059426 |
| GO:0046620 | Regulation of organ growth | Affects phenotype | PMID:8125204 |
| GO:0046960 | Sensitization | Increases phenotype | PMID:28194001 |
| GO:0048148 | Behavioral response to cocaine | Increases phenotype | PMID:30483076; PMID:33427014; PMID:33427014; PMID:35597300; PMID:35597300 |
| GO:0051560 | Mitochondrial calcium ion homeostasis | Affects phenotype | PMID:30027653 |
| GO:0051623 | Positive regulation of norepinephrine uptake | Increases phenotype | PMID:25724654 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:29475069; PMID:30027653; PMID:31494168 |
| GO:0060079 | Excitatory postsynaptic potential | Affects phenotype | PMID:18184795; PMID:18216231; PMID:8385746; PMID:8774428 |
| GO:0060080 | Inhibitory postsynaptic potential | Decreases phenotype | PMID:11790512 |
| GO:0061370 | Testosterone biosynthetic process | Decreases phenotype | PMID:31059705 |
| GO:0071314 | Cellular response to cocaine | Increases phenotype | PMID:30483076 |
| GO:0090326 | Positive regulation of locomotion involved in locomotory behavior | Increases phenotype | PMID:30483076 |
| GO:0090494 | Dopamine uptake | Decreases phenotype | PMID:33269408 |
| GO:0140591 | Nuclear envelope budding | Increases phenotype | PMID:37271276 |
| GO:1900409 | Positive regulation of cellular response to oxidative stress | Increases phenotype | PMID:30027653 |
| GO:1900745 | Positive regulation of p38mapk cascade | Increases phenotype | PMID:25724654 |
| GO:1901671 | Positive regulation of superoxide dismutase activity | Increases phenotype | PMID:30027653 |
| GO:1901676 | Positive regulation of histone h3-k27 acetylation | Increases phenotype | PMID:32312805 |
| GO:1902721 | Negative regulation of prolactin secretion | Increases phenotype | PMID:12893845 |
| GO:1903283 | Negative regulation of glutathione peroxidase activity | Increases phenotype | PMID:30027653 |
| GO:1903296 | Positive regulation of glutamate secretion, neurotransmission | Increases phenotype | PMID:26283212 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:29475069; PMID:30393195; PMID:31059705 |
| GO:1990708 | Conditioned place preference | Increases phenotype | PMID:26052038; PMID:32095523 |
| GO:2000253 | Positive regulation of feeding behavior | Increases phenotype | PMID:27126842 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.